Andrew King

Andrew King

Company: Chinook Therapeutics

Job title: Chief Scientific Officer


Panel Discussion: Thinking Outside the Box: Innovative Approaches to Reshaping Clinical Trial Design to Streamline Clinical Development 12:30 pm

Examining exclusion criteria to expand the treatable population and strategizing to modify design aspects without undermining integrity and validity Overcoming the impact of the pandemic on clinical research: decentralized approaches to clinical trials Exploring opportunities for basket trials, umbrella trials and platform trials in the context of rare and genetic kidney diseases Considering regulatory perspectives…Read more

day: Day Two

Discovery & Characterization of Liver-Targeted Small Molecule Inhibitors of Lactate Dehydrogenase A (LDHA) for the Treatment of Primary Hyperoxaluria (PH) 12:00 pm

Delve into how PH 1-3 cause excess hepatic oxalate production, resulting in frequent kidney stone formation, progressive CKD and in its most severe form, PH1 can lead to ESKD at a young age Learn how LDHA catalyzes the final step in hepatic oxalate synthesis and therefore represents a potential therapeutic target to treat all forms…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.